Latest TAK news and sentiment

Climate-ready healthcare: Our 2026 global CSR programs

Takeda announced its 2026 global Corporate Social Responsibility (CSR) programs, committing USD 22.2 million to four new multi-year projects aimed at strengthening climate-resilient health systems worldwide. These initiatives, chosen by Takeda employees, will support organizations like Corus International, Humanity & Inclusion – Handicap International, Kwame Nkrumah University of Science and Technology, and Terre des hommes Foundation in countries such as Nepal, Honduras, Peru, Ghana, Egypt, and Lebanon. The programs focus on areas including early warning systems, resilient service delivery, workforce capacity building, and greener practices to address the widespread impact of climate change on global health outcomes.

Takeda Pharmaceutical Company Limited (4502.T) Stock Price, News, Quote & History

This article provides comprehensive financial data for Takeda Pharmaceutical Company Limited (4502.T), including its current stock price, dividend information, key financial metrics, performance overview, and analyst insights. The company recently announced a cash dividend and has shown significant year-to-date and annual returns. Takeda operates in the pharmaceutical industry, focusing on gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

Roche proposes former Takeda CEO for board seat

Roche announced its proposal to elect Christophe Weber, the former CEO of Takeda Pharmaceuticals, to its board of directors at its upcoming Annual General Meeting in March. Roche Chairman Severin Schwan stated that Weber's extensive knowledge of the healthcare industry and leadership experience would significantly strengthen the board. This move signals Roche's intention to enhance its leadership with seasoned pharmaceutical expertise.

Takeda’s new president aims to increase line of drug candidates

Julie Kim, the new president of Takeda Pharmaceutical Co., is focused on accelerating drug development through the integration of AI and new technologies. She aims to establish Takeda as a world leader in its priority fields by strengthening its drug pipeline, including three new medicines slated for release within the next year. Kim, the company's first female president, emphasizes the importance of a robust line of potential drug candidates for long-term growth, building on the globalization efforts initiated by her predecessor, Christophe Weber.

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric Cancer TAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLC Takeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy OSAKA, Japan & CAMBRIDGE, Mass., September 22, 2026--(BUSINESS WIRE)--Takeda(TSE:4502/NYSE:T

Takeda Pharmaceutical Co cuts FY26 adj EPS to $2.96, sales to $29.1B

Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history

What Is Drawing Fresh Attention To Takeda Pharmaceutical (TSE:4502)?

Takeda Pharmaceutical (TSE:4502) has received a boost from the U.S. FDA's acceptance of its New Drug Application for zasocitinib in plaque psoriasis, leading to a recent surge in its stock price. Despite a 9% undervaluation by analysts, concerns about generic competition and potential drug trial setbacks present risks. The company's pipeline in psoriasis and narcolepsy is seen as a key driver for future growth.

Takeda and Dr. Reddy's Laboratories enter into exclusive collaboration to promote and distribute QDENGA in India's pediatric and adult private market

Takeda and Dr. Reddy's Laboratories have announced an exclusive collaboration to promote and distribute Takeda's dengue vaccine, QDENGA, in India's private market for pediatric and adult vaccination. This partnership follows the vaccine's marketing authorization approval by India's CDSCO in July 2026, making it the country's first approved dengue vaccine. The collaboration aims to make QDENGA available in India by the first half of 2027, leveraging Dr. Reddy's extensive network to address the significant public health challenge posed by dengue in India.

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

Dr Reddy's Laboratories has signed an agreement with Takeda Pharmaceutical to distribute and promote the Qdenga dengue vaccine in India. The vaccine, approved by India's drug regulator for children and adults, is expected to be available in early 2027. This partnership addresses the significant public health challenge posed by dengue, a rapidly spreading mosquito-borne disease.

Dr. Reddy's, Takeda Sign Deal to Distribute QDENGA Dengue Vaccine in India

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh) Commitment of USD 22.2 Million Increases Takeda's Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries OSAKA, Japan & CAMBRIDGE, Mass., September 18, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as

Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call

Takeda Pharmaceutical Co reported Q1 2026 results, showing core revenue and operating profit declines of 0.5% at constant exchange rates, aligning with expectations. The company is focused on its Two-Horizon strategy, with key product launches for Orzafl, Rusfertide, and Zazositinib expected in late 2026 and early 2027, backed by a robust R&D pipeline and ongoing transformation programs. Takeda reaffirmed its full-year guidance and commitment to strong free cash flow and financial discipline, with a Capital Markets Day scheduled for December 11, 2026, to detail its long-term ambitions.

Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date falls in the first quarter of calendar 2027, creating a defined regulatory window for the investigational once-daily oral treatment. Zasocitinib inhibits tyrosine kinase 2, or TYK2, which participates in inflammatory signaling. For investors, the opportunity rests on combining meaningful skin clearance with oral convenience. Approval, prescribing restrictions an

Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation O

Takeda's Investigational Plaque Psoriasis Drug Accepted for Priority Review by US FDA

FDA accepts Takeda’s zasocitinib application for plaque psoriasis

The FDA has accepted Takeda's New Drug Application for zasocitinib (TAK-279) for moderate-to-severe plaque psoriasis, granting it Priority Review with a target action date in Q1 2027. This investigational oral drug demonstrated significant skin clearance in Phase 3 studies, with approximately 70% of patients achieving clear or almost clear skin by week 16. The European Medicines Agency also accepted Takeda’s marketing authorization application for the drug.

Takeda Pharmaceutical (TAK) Stock Price, News & Analysis $TAK

Former head of Takeda Pharmaceutical dies at 80

Yasuchika Hasegawa, former president of Takeda Pharmaceutical and former chair of the Japan Association of Corporate Executives, died at 80 on July 3 in Tokyo. He was instrumental in Takeda Pharmaceutical's globalization, overseeing a major acquisition and inviting its first foreign president. Hasegawa was also recognized for his leadership during the 2011 earthquake and tsunami disaster and his contributions to the Trans-Pacific Partnership deal.

Takeda Pharmaceutical Co cuts FY26 adj EPS to $2.96, sales to $29.1B

Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026

Trialbee continues to bring fresh innovation to clinical trials with its Honey Platform™, demonstrating how AI is reshaping patient recruitment – and where it goes from here MALMO, Sweden & WILMINGTON, Del., September 09, 2026--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15–16 in Boston. During the event, Trialbee will unveil AI patient screening in its Honey Platform™, the next release on the Applied AI Recruitment roadmap it published earlier this year. Trialbee will

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks. On